Premature Ovarian Insufficiency stem cell therapy — your questions answered (2026)

About stem cell therapy for Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) is loss of ovarian function before age 40, confirmed through menstrual history and biochemical assessment. It can affect fertility, bone, cardiovascular, sexual and psychological health. Causes and residual ovarian activity vary. Mesenchymal stromal cells (MSCs) and other biological approaches are being studied, but proposed follicle, hormonal or immune mechanisms have not established restored fertility or live birth. Cell injection or infusion is not standard POI care. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for Premature Ovarian Insufficiency

POI cell-therapy evidence is early and heterogeneous. Menstruation, hormone levels, ultrasound follicles, oocyte retrieval, pregnancy and live birth are different outcomes and must not be treated as interchangeable. Small uncontrolled series cannot establish that an intervention restored ovarian function or caused a pregnancy. No pooled response rate is published here because product, route, patient selection and endpoints differ too widely. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational POI cell procedures can involve separate charges for ovarian injection, anaesthesia, hormone testing, imaging, fertility treatment, cryopreservation, monitoring and travel. Prices do not indicate regulatory approval, ovarian restoration or pregnancy benefit. Patients should request an itemised written quote separating research procedures from IVF and standard care, and verify sponsor, insurer and patient responsibilities.

Can stem cells restore ovarian function?

Cell therapy for Premature Ovarian Insufficiency may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Who is a candidate?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

Realistic chances?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Premature Ovarian Insufficiency programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Premature Ovarian Insufficiency (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Premature Ovarian Insufficiency overview · Premature Ovarian Insufficiency cost →